InDevR | GenomeWeb

InDevR

The certification comes ahead of the company's planned launch of a microarray-based test for differentiating seasonal and non-seasonal influenza viruses.

St. Jude's Richard Webby will assess the performance of InDevR's FluChip-8G test on non-seasonal influenza viruses.

Agilent Technologies this week announced updates to its SurePrint miRNA Microarrays to include targets from the latest version of the miRBase public miRNA database.

NEW YORK (GenomeWeb) — Researchers at Johns Hopkins University have performed the first validation of the Cepheid Xpert Flu assay in a population of emergency room patients with acute undifferentiated respiratory illness.

NEW YORK (GenomeWeb) – By the end of 2016, InDevr aims to have a microarray-based clinical test on the market for genotyping influenza viruses.

NEW YORK (GenomeWeb) – InDevr announced today that it has signed a contract with the Biomedical Advanced Research and Development Authority to finish the development of a microarray-based test for influenza.

Applied Microarrays and InDevR this week announced a new partnership that will pair AMI's contract array manufacturing resources with InDevR's instrumentation and assay development capabilities.

NEW YORK (GenomeWeb) – InDevR and Applied Microarrays said today that they will work together to offer custom microarrays, instruments, and reagents for multiplexed assays.

Indevr recently launched its AmpliPhox system for nucleic acid and protein microarray analysis.

Pages

Biomedical research projects are generating a ton of data that still needs to be analyzed, NPR reports.

Theranos is retiring some of its board members, including Henry Kissinger and George Shultz, Business Insider reports.

The heads of 29 scientific societies and some 2,300 researchers call on President-elect Donald Trump to rely on and support science in two separate letters.

In Science this week: genetically modified flu virus could be key to new live vaccines, and more.